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Telomeres are specialized structures responsible for the chromosome end protection. Previous studies have revealed that
defective BRCA1 may lead to elevated telomere fusions and accelerated telomere shortening. In addition, BRCA1 associ-
ates with promyelocytic leukemia (PML) bodies in alternative lengthening of telomeres (ALTs) positive cells. We report
here elevated recombination rates at telomeres in cells from human BRCA1 mutation carriers and in mouse embryonic
stem cells lacking both copies of functional Brca1. An increased recombination rate at telomeres is one of the signs of
ALT. To investigate this possibility further we employed the C-circle assay that identifies ALT unequivocally. Our results
revealed elevated levels of ALT activity in Brca1 defective mouse cells. Similar results were obtained when the same cells
were assayed for the presence of another ALT marker, namely the frequency of PML bodies. These results suggest that
BRCA1 may act as a repressor of ALT. VC 2016 The Authors Genes, Chromosomes & Cancer Published by Wiley Periodicals, Inc.
INTRODUCTION
Telomeres are unique DNA–protein structures
responsible for chromosome end protection. The
loss of telomere function causes end-to-end chromo-
some fusion, cell cycle arrest and apoptosis or cellu-
lar senescence (Blasco et al., 1997; de Lange, 2015).
In humans, telomere dysfunction leads to genetic
and common diseases including cancer (Harley
et al., 1990; Blackburn et al., 2015). Understanding
the mechanisms behind telomere structural and
length maintenance can be beneficial to understand-
ing mechanisms of some human diseases, and also
physiological processes such as aging.
Two tumor suppressors, BRCA1 and BRCA2,
play a role in maintaining telomere integrity
(McPherson et al., 2006; Min et al., 2012; Roy
et al., 2012). BRCA1 is involved in DNA damage
repair through nonhomologous end joining
(NHEJ) and homologous recombination (HR)
(Moynahan et al., 1999; Cao et al., 2003; Davalos
and Campisi, 2003; Ohta et al., 2011). The lack of
functional BRCA1 leads to radiosensitivity and
telomere dysfunction (Foray et al., 1999; Trenz
et al., 2002; Acharya et al., 2014; Sedic et al.,
2015). The DNA damage sensor, the MRN com-
plex, usually recruits BRCA1 to the DNA damage
sites (Rosen, 2013). This acts as a signal for
recruiting other proteins involved in the DNA
double-strand break (DSB) repair pathways such
as RAD51 (Rosen, 2013). It has also been
shown that BRCA1 may have a role, through inter-
acting with BLM and Rad50, in the alternative
lengthening of telomere (ALT) pathway. How-
ever, the exact mechanism behind the potential
BRCA1 role in ALT remains unclear.
Many DNA damage response proteins act as
partners of BRCA1 in various pathways. In a
recent study, it was shown that primary human
mammary epithelial cells (HMECs) with muta-
tions in BRCA1 (mut/1) show premature senes-
cence as a result of genomic instability (Sedic
et al., 2015). This unique type of cellular senes-
cence caused by haploinsufficiency of a tumor sup-
pressor is termed haploinsufficiency-induced
senescence (HIS) (Sedic et al., 2015). The sponta-
neous bypass of this senescence pathway is
thought to be involved in the early onset of breast
cancer in individuals with BRCA1 mutations
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(Sedic et al., 2015). Although these immortalized
nontumorigenic BRCA1 mut/1 HMECs showed
rapid genomic instability, increased DNA damage
and telomere erosion, the exact mechanism by
which the telomere maintenance is affected is not
known (Sedic et al., 2015). Recent findings sug-
gest that BRCA1 accumulates at telomeres in the
ALT-positive cancer cells, most likely with the
help of BLM and PML bodies (Acharya et al.,
2014). Furthermore, BRCA1 may be involved in
end-processing and fusion of uncapped telomeres
through the A-NHEJ (alternative NHEJ) pathway
together with its interacting partner CtIP (Badie
et al., 2015).
The activities of BRCA1 and BLM at telomeres
have only been recognized recently (Acharya
et al., 2014). BRCA1 is required for recombination
proteins to promote strand processing and invasion
and to form recombination intermediates. The
process requires BLM during G2 phase of the cell
cycle (Acharya et al., 2014). However, this role is
different from the role played by the BRCA1–
RAD50 complex during the Sphase (Maser and
DePinho, 2002; Davalos and Campisi, 2003).
Although BRCA1 may have an important func-
tional role in the ALT pathway (which utilize HR
for telomere length homeostasis), the mechanism
of this process is not fully understood.
This study provides further evidence for the
involvement of BRCA1 in telomere maintenance
and shows that the lack of functional BRCA1 may
enhance levels of the ALT activity.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
Lymphoblastoid cell lines from BRCA1 muta-
tion carriers (GM14090 and GM13705) and a con-
trol cell line (GM00893) were obtained from the
Coriell Cell Repository and maintained in
RPMI1640 medium (Gibco, Thermo Fisher Scien-
tific, Waltham, MA) supplemented with 10% fetal
calf serum as described previously (Castilla et al.,
1994; Struewing et al., 1995). The HCC1937 cell
line was kindly provided by Dr M. Zdzienicka,
University of Leiden the Netherlands and main-
tained in RPMI 1640 medium (Gibco, Thermo
Fisher Scientific, MA) with 15% fetal calf serum.
Mouse embryonic stem cells (mESCs) E14 and
E408 (from here on referred to as 408) were kindly
provided by Dr Beverly Koller Duke University
(United States) and were cultured at 378C in the
atmosphere of 5% CO2 on Gelatine (Sigma-
Aldrich, St Louis, MO) coated dishes in Knockout
Dulbecco’s modified Eagle’s minimal essential
medium (D-MEM) (Gibco, Thermo Fisher Scien-
tific, MA) and supplemented with 20% KnockOut
serum replacement as described (Snouwaert et al.,
1999). U2OS and G292 cell lines were cultured in
the McCoys 5A medium (Gibco, Thermo Fisher
Scientific, MA), supplemented with 10% fetal
bovine serum. HeLa and SKLU-1 cell lines were
cultured in the D-MEM supplemented with 10%
fetal bovine serum. All cell lines were maintained
at 378C (humidified incubator LEEC) with 5% car-
bon dioxide content except HeLa and U2OS,
which were maintained in the atmosphere containing
10% of carbon dioxide. Details of all cell lines used
in this study including the type of BRCA1 mutation
is listed in Supporting Information Table S1.
Irradiation
Cells were exposed to ionizing radiation using a
Cobalt60 source (0.6859 Gy min21). Adherent cells
were grown to 80–90% confluence either in nonfil-
tered tissue culture flasks (Nunc, Thermo Fisher
Scientific, MA) for metaphase preparation, or on
Poly-prep slides (Sigma-Aldrich) depending on
the experimental protocol. Cells were exposed to
different doses of ionizing radiation including: 0.5
Gy, 1.0 Gy, 2.0 Gy, and 4.0 Gy.
Telomere Sister Chromatid Exchange (T-SCE)
Analysis Using Chromosome Orientation
Fluorescence In Situ Hybridization (CO-FISH)
Metaphase preparation and CO-FISH were per-
formed as described (Bailey et al., 2004). Cells
were split and subcultured in the fresh medium
containing a 3:1 ratio of 5-bromo-2-deoxyuri-
dine:5-bromodeoxycytidine (Sigma-Aldrich) at a
final concentration of 1 3 1025 M for 24 hr for
human and 17 hr for mouse cell lines. Colcemid
(0.1 mg/ml) was added for the final 4 hr of
incubation.
Immunofluorescence
The list of all antibodies is shown in Supporting
Information Table S2. In brief, cells were washed
with phosphate buffered saline (PBS) and then
permeabilized for 10 min on ice with cold PBS
and 0.5% triton X-100 (Sigma-Aldrich). The cells
were washed with cold PBS 4 3 5 min and were
blocked with 0.2% (w/v) cold water fish gelatin
(Sigma G-7765), 0.5% (w/v) BSA (Sigma A-2153)
in PBS for at least 30 min at room temperature.
Primary antibodies were diluted according to Sup-
porting Information Table S2 and incubated for 1
ALT MARKERS IN BRCA1 CELLS 865
Genes, Chromosomes & Cancer DOI 10.1002/gcc
hr at room temperature. The secondary antibodies
were added again according to the dilutions set out in
Supporting Information Table S1 for 1 hr following
three rounds of washes in PBS with 1% tween-20.
The slides were washed in PBS and Cy3-conjuated
PNA probe (CCCTAA)3 was applied for 2–3 min at
808C, followed by standard formamide and saline-
sodium citrate (SSC) washes. Finally, cells were
mounted with coverslips using 40, 60-diamidino-2-
phenylindole (DAPI)-containing mounting medium
(Vector Laboratories, Burlingame, CA).
Telomere Dysfunction-Induced Foci (TIF) Analysis
Combined immunofluorescence (g-H2AX) and
FISH (telomeric PNA probe) to detectDNA dam-
age at telomeres is usually known as TIFs (Yasaei
and Slijepcevic, 2010). First, detection of g-H2AX
foci by immunofluorescence was performed. Slides
were incubated overnight in a dark container at
room temperature. The following day, FISH with
a Cy3-conjugated PNA telomeric probe
(CCCTAA)3 as described above, was performed
followed by formamide and SSC washes. Cells
were counterstained with DAPI. The slides were
analyzed using the computerized Zeiss Axioskop 2
fluorescence microscope equipped with a CCD
camera and Metasystem software (Altlussheim,
Germany).
Telomere Length Analysis Using Interphase
Quantitative FISH (IQ-FISH)
To measure telomere signals in the interphase
nuclei we followed a protocol previously described
(Ojani, 2012). A total of 50 interphase cells per cell
line were analyzed and the mean telomere fluores-
cence intensity was determined for each cell line.
The integral part of the method is the use of two
mouse lymphoma cell lines, LY-R and LY-S, as
calibration standards. These cell lines have stable
telomere lengths of 49 kb and 7 kb, respectively
(McIlrath et al., 2001; Cabuy et al., 2004, 2005;
Yasaei and Slijepcevic, 2010). Using the values of
telomere fluorescence obtained for LY-R and LY-
S cells, the corrected calibrated fluorescence
(CCFL) was calculated for the two human lym-
phoblastoid cell lines BRCA1 defective cell lines
(GM13705 and GM14090) and mESCs (E14 and
408) using the following formula: CCFL5CF 3
FLx, where CF is the final correction factor,
CCFL represents Corrected Calibrated Fluores-
cence and FLx represents unmodified fluorescence
of the sample under investigation.
Telomerase Repeat Amplification Protocol
(TRAP)
We followed the manufacturer’s guidelines for
the TRAP assay (Millipore, Billerica, MA) and
these have been described in detail previously
(Kim et al., 1994; Yang et al., 2007). All cell pellets
were resuspended in the 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate (CHAPS;
Millipore Company) detergent lysis method. The
protein concentration of the samples was deter-
mined using the Pierce BCA Protein Assay Kit
(Thermo Scientific) according to the manufac-
turer’s protocol. For all TRAP PCRs, we used 200
ng of CHAPs lysed protein and performed three-
independent experiments.
C-Circle Assay
The full working protocol of C-circle (CC) assay
was kindly provided by Prof Roger Reddel (Child-
ren’s Medical Research Institute, University of
Sydney, Australia) and described in detail previ-
ously (Henson et al., 2009). In short, the level of
CC is measured through a two-step process: DNA
amplification using Phi-29 DNA polymerase and
nucleotide lacking dCTP followed by radio-
labeled (P32) probing and hybridization using
(CCCTAA)3 oligonucleotide. Total genomic DNA
was extracted from cell pellets of various cell lines
using QIAmp DNA Mini Kit (Qiagen, Hilden,
Germany) by following the manufactures guide-
line. 20 ng or 30 ng gDNA was used for all PCRs
according to the published protocols (Henson
et al., 2009).
Immunoblotting
Western blot analysis was performed to quantify
the BRCA1 protein expression. A total of 15 3 105
cells were centrifuged and washed with ice-cold
PBS and lysed in lysis buffer (Tris-HCl (1 M, pH
7.4), NaCl (5 M), EDTA (0.5 M, pH 8.0), Triton
X-100 (1%), SDS (10% w/v), Na-deoxycholate
(10% w/v), Protease Inhibitor (Roche Diagnostics,
Penzberg, Germany) (73) nuclease-free water and
incubated on ice. The protein extracts were mixed
with SDS-PAGE loading buffer and loaded in a
gradient gel (Mini-Protean TGX stain-free gels,
Bio-rad, Hercules, CA), were transferred to a
PVDF membrane (Thermo Fisher Scientific).
The primary antibodies were used were BRCA1
and b-Actin as a loading control. The HRP-
conjugated, secondary antibodies used were anti-
mouse IgG and anti-goat.
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Statistical Analysis
All statistical tests and graphical drawings were
performed on GraphPad PRISM version 6. Stu-
dent t-test was used for all statistical analyses with
95% confidence interval (a5 0.05) unless other-
wise stated.
RESULTS
Human BRCA1 Mutation Carrier Cells Show
Elevated T-SCE Frequencies
We have previously demonstrated that lympho-
blastoid cell lines from BRCA1 mutation carriers
(GM14090 and GM13705) show signs of telomere
dysfunction as evidenced by the increase in chro-
mosome end-to-end fusion (Al-Wahiby and Slijep-
cevic, 2005). This was accompanied by telomere
shortening as measured by the conventional Q-
FISH. To investigate if there are other signs of
telomere dysfunction in these lines we analyzed
spontaneous frequencies of T-SCEs using the
CO-FISH technique. We found, on average, a
twofold higher frequency of T-SCEs in the
BRCA1 mutation carrier cell lines relative to the
control cell line (Figs. 1A and 1B). In a total of 200
cells analyzed we observed 142 and 108 T-SCEs
in GM14090 and GM13705, respectively, com-
pared with only 62 T-SCEs in the control cell line
(Figs. 1A and 1B). To confirm that BRCA1 muta-
tion carrier cell lines show shorter telomeres we
performed IQ-FISH. This technique relies on the
higher number of cells than the conventional Q-
FISH, thus increasing the statistical power. In line
with our previous observation (Cabuy et al., 2005),
the IQ-FISH data showed that BRCA1 mutation
carrier lines had significantly shorter telomeres
compared with the control line (P< 0.0001) (Figs.
1C–1E).
Next, we analyzed the frequencies of TIFs in
the above-mentioned cell lines. The cell lines
from BRCA1 mutation carriers showed a twofold
increase in the levels of spontaneous g-H2AX foci
relative to the control cell line (Fig. 2A and Sup-
porting Information Fig. S1A) suggesting higher
levels of unrepaired DNA DSBs due to lack of
Figure 1. Human BRCA1 heterozygote lymphoblastoid cells show
higher levels of sister chromatid exchanges: (A) CO-FISH analysis for
telomere sister chromatid exchanges revealed a significantly higher
level of T-SCE in the two BRCA1 heterozygote cells compared with the
normal counterpart. (B) Examples of CO-FISH showing elevated levels
of T-SCE (arrows). (C) Telomere length measurement using interphase
Q-FISH showed significantly shorter telomeres in the two BRCA1 het-
erozygote cells. (D) The average telomere lengths of the LY-R and LY-S
mouse lymphoblastoid cells were used to normalize the telomere
probe intensity. (E) An average of 50 interphase nuclei was measured
from the two mouse cells. All exposures were fixed at 0.5 sec. Error
bars represent standard error of the mean (SEM). In all cases a mini-
mum of 50 cells was analyzed in two-independent experiments. Note:
HCC1937 (BRCA11/2) cell line had CCFL of 6.95 (SEM 0.84) when
normalized to the LY-R and LY-S cells. 50 HCC1937 cell nuclei were
scored for IQ-FISH measurement. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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functional BRCA1. As expected, the repair of
DNA DSBs in BRCA1 mutation carrier lines was
significantly delayed relative to the control line
(Fig. 2B). Furthermore, DNA damage followed a
dose–response pattern with a clear distinction
between the normal line and BRCA1 mutation car-
rier lines (Fig. 2C).
When the spontaneous levels of TIF were ana-
lyzed, we found 1.0–1.2 TIFs/cell in BRCA1 muta-
tion carrier cells compared with 0.5 TIFs/cell in
the control line (Fig. 2D and Supporting Informa-
tion Fig. S1A). The kinetics of TIFs after expo-
sure of the cells to IR revealed inability of BRCA1
mutation carrier lines to restore the TIFs fre-
quency to preirradiation levels unlike the control
line (Fig. 2E). The dose-response analysis
revealed dramatic increase in TIF frequency in
BRCA1 mutation carrier lines (Fig. 2F).
Taken together these results suggest that
BRCA1 is implicated in telomere maintenance.
Importantly, the significant increase in T-SCEs
frequencies in BRCA1 mutation carrier lines could
be indicative of ALT activity as T-SCEs are usu-
ally elevated in ALT-positive cell lines (Londono-
Vallejo et al., 2004; Neumann and Reddel, 2006).
Elevated T-SCEs in Brca1 Defective Mouse Cells
To investigate if increased frequencies of T-
SCEs occur regularly as a result of BRCA1 dys-
function we used the Brca12/2 mESC line, 408,
and its normal counterpart, E14 (Snouwaert et al.,
1999). We found a nearly threefold higher T-SCE
frequency in the 408 cell line relative to the con-
trol E14 cell line (Figs. 3A and 3B). In addition,
we observed a twofold increase in telomere fusions
in 408 cells (Figs. 3C and 3D) and significantly
shorter telomeres relative to the control line (Figs.
3E and 3F). The analysis of DNA damage foci
(Figs. 4A and 4B) and TIFs (Figs. 4C and 4D)
revealed, similarly to human lines, inability of 408
cells to repair DNA damage and TIFs to
Figure 2. Analysis of the kinetics of repair of g-H2AX and TIF
revealed telomere dysfunction phenotypes: (A) Levels of spontaneously
induced g-H2AX. (B) Repair kinetics after 1.0 Gy of radiation-induced
g-H2AX showing delayed repair kinetics in the two human BRCA1
heterozygote lymphoblastoid cells. (C) A dose–response curve show-
ing g-H2AX levels after 0.5 Gy, 1.0 Gy, and 2.0 Gy of the IR. (D)
Spontaneous levels of TIFs in the two BRCA1 heterozygous lympho-
blastoid cells. (E) A significantly higher levels of TIFs persist 48 hr after
1.0 Gy IR in the two BRCA1 heterozygous lymphoblastoid cells. (F)
Similar differences in the levels of TIFs in the two lymphoblastoids
BRCA1 heterozygous cells when exposed to 0.5 Gy, 1.0 Gy, and 2.0 Gy
of IR with levels of TIFs peaking at 2.0 Gy. (G) t-Test analysis compar-
ing untreated g-H2AX foci per cell in each sample with 1.0 Gy irradia-
tion. Asterisks indicate the level of significance (**P< 0.01,
***P< 0.001). Error bars represent SEM. In all experiments a minimum
of 50 cell nuclei was analyzed in at least two-independent experiments.
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preirradiation levels in comparison with the con-
trol E14 line ( Supporting Information Fig. S1B).
The only difference was an extremely high spon-
taneous frequency of g-H2AX foci in mESCs (Fig.
4A) in comparison with human lines (Fig. 2A).
This is in agreement with previous reports that
suggested that elevated frequencies of g-H2AX in
mESCs could result from epigenetic mechanisms
rather than from DNA damage (Turinetto et al.,
2012). In addition, the analysis of radiation-
induced chromosomal aberrations revealed greater
sensitivity of 408 cells (Figs. 4E and 4F). There-
fore, these results suggest that Brca12/2 mESCs
show clear telomere dysfunction and confirm that
frequencies of T-SCEs are elevated relative to
control cells.
C-Circle Analysis Reveals Increased ALT Activity
in the Brca1 Defective Mouse Embryonic Stem
Cells
Since we observed higher levels of T-SCEs in
human and mouse cells lacking functional BRCA1
relative to control cells, and given that frequencies
of T-SCEs are elevated in ALT-positive cell lines
(Londono-Vallejo et al., 2004; Neumann and Red-
del, 2006), this observation could be indicative of
a potential ALT activity in affected cells. The
gold standard method for identifying ALT activity
is the CC assay (Henson et al., 2009; Henson and
Reddel, 2010). Therefore, to investigate if the
observed elevated T-SCE frequencies represent a
sign of ALT activity we performed the CC assay
in (i) cell lines with dysfunctional BRCA1 and (ii)
Figure 3. Sister chromatid exchanges, telomeric fusions and telo-
mere length analysis reveals dysfunctional telomeres in the Brca1
defective mESCs: (A) CO-FISH analysis reveals increased levels of T-
SCEs in the Brca1 defective mESC (408). (B) CO-FISH example show-
ing T-SCEs measured in the two mESCs. (C) Telo-FISH analysis show-
ing higher levels of spontaneously generated telomeric fusions in the
Brca1 defective 408 cells. (D) Examples of telomeric fusions in the two
mESCs. Arrow showing sites of telomeric fusions. (E) Telomere length
analysis using interphase Q-FISH normalized to the LY-R and LY-S cells.
The data show threefold reduction in the telomere lengths in the 408
Brca1 defective mESC. (F) Examples of interphase cells with telomeric
probes in green. A reduced telomeric signal is seen in the 408 cells. A
total of 50 metaphases was analyzed in two-independent experiments.
A minimum of 50 cell nuclei was captures and telomeric signal meas-
ured with exposure set at 0.5 sec in two-independent experiments.
Error bars indicate SEM. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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a range of control ALT- or telomerase-positive cell
lines ( Supporting Information Table S1).
As expected, ALT-positive cell lines (U2OS,
SKL-U1, and G292) showed a robust ALT activity
(Fig. 5A). To investigate ALT in other cell lines
in a quantitative way we normalized the values
observed so that the value observed for the U2OS
cell line represents 1 arbitrary unit (a.u.) (Fig. 5A).
We have also generated a calibration curve using
serial dilutions of gDNA from the U2OS cell line
(Fig. 5C). None of the human telomerase-positive
cell lines, such as HeLa (Fig. 5E) and a cell line
from a BRCA1 mutation carrier (GM13705) or the
cell line completely lacking functional BRCA1
(HCC1937; see Fig. 5D; telomerase activity data
not shown), exhibited visible ALT activity, at
least after the quantification based on analyzing
images with the J-image software when using
Figure 4. g-H2AX, TIF and chromosomal aberration analysis in the
Brca1 defective mouse embryonic stem cells: (A) Spontaneous levels of
g-H2AX in the mouse Brca1 wt (E14) and defective (408) ES cells. (B)
Repair kinetics measured using g-H2AX after exposure to 1.0 Gy of
IR. (C) Levels of spontaneous TIFs in the two mESCs. (D) Mean TIF
levels in the two mESCs showing a delayed repair of the telomeres. (E)
A dose response curve of CA measured in the G1-phase after expo-
sures to 0.5 Gy, 1.0 Gy, 2.0 Gy, and 4.0 Gy of the IR. (F) A time-
course experiment showing frequencies of CA measured in the G2-
phase after exposure to 1.0 Gy. A minimum of 50 cell nuclei was ana-
lyzed for g-H2AX and TIFs and 100 metaphase cells analyzed for CA
studies in two-independent experiments. Asterisks indicate the level of
significance (**P< 0.01, ***P< 0.001). Error bars represent SEM. CA,
chromosomal aberration.
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U2OS as the normalizing standard (Fig. 5A). How-
ever, some signals are visible in the lanes repre-
senting the HeLa, GM00893, GM13705, and
HCC1937 cell lines suggesting that the value of
CC activity is not 0 in these lines. When the signal
generated for the U2OS line is used as the normal-
izing standard it leads to 0 values in cells with
weak signals.
To investigate whether weak signals differ
between themselves we used the signal generated
by the HeLa cell line as the normalizing standard.
This analysis, revealed that the GM13705 and
HCC1937 cell lines show higher ALT activity
than the HeLa and GM00893 cell lines (Fig. 5B),
however, the increase was not significant
(P5 0.1210). All four human cell lines featuring
weak CC-assay signals showed telomerase activity
(Fig. 5E and data not shown).
In contrast to human telomerase-positive cell
lines in which ALT activity was detectable but
Figure 5. C-circle assay showed ALT activity in the mESCs: (A) CC
assay indicating recombination activity normally associated with ALT.
20 ng of gDNA were used to measure levels of CC and quantified rel-
ative to the U2OS for the human cells and E14 for the mouse cells.
The two mouse ESCs show ALT activity with the Brca1 defective 408
showing higher ALT activity. (B) Four human telomerase-positive cell
lines () showed basal ALT activity and when measured using the Image
J analysis software, elevated ALT activity in the two BRCA1 defective
cell lines (GM13705 and HCC1937) compared with the control coun-
terparts. (C) U2OS ALT-positive human cells used to draw a standard
curve and showing the sensitivity of the assay. (D) Immunoblotting
showing lack of Brca1 in the mouse 408 cells and reduced BRCA1
activity in the human breast cancer cells HCC1937. Anti-beta actin
used as loading control. (E) TRAP assay revealing telomerase activity in
200 ng of CHAPS-lysed protein lysate of the human HeLa and
HCC1937 cancer cells but not in the U2OS osteosarcoma cells. Both
mouse ESCs show telomerase activity but the activity is lower in the
408 cells. (F) Quantification of the TRAP gel measuring the telomerase
activity from 200 ng of the CHAPS-lysed protein lysate. Three TRAP
assays were performed using three-independently extracted lysates.
TSR8 is the quantitation control. SI-C is the standard internal control.
Heat treatment was done at 958C for 10 min. The error bars indicate
standard deviation. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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very low, both mouse cell lines showed a strong
ALT activity (Fig. 5A). The control E14 cell line
had a degree of ALT activity comparable to that
in the U2OS cell line, whereas the Brca12/2 408
cell line showed the highest recorded ALT activ-
ity: 50% higher than that measured in the U2OS
and E14 cell lines (P5 0.0341) using 30 ng of
gDNA (Fig. 5A). We observed a similar significant
difference in the CC-activity when using 20 ng of
gDNA between E14 and 408 cells (data not
shown) (P5 0.0119). Mouse cell lines did not dif-
fer in terms of telomerase activity (Figs. 5E and
5F). These results are in line with a recent study
that showed coexistence of the ALT activity and
telomerase in mouse cells (Perrem et al., 2001;
Neumann et al., 2013). Our results suggest that
the ALT activity is significantly elevated in the
mouse Brca1 defective environment.
Immunofluorescence Analysis
In addition to the CC assay another indicator of
ALT is detection of APBs (ALT-associated PML
Bodies) (Yeager et al., 1999; Henson et al., 2002;
Neumann and Reddel, 2006). We observed a sig-
nificant difference between the 408 and E14 cell
lines in the levels of APBs (P5 0.0002) (Fig. 6A).
This also held true for the HCC1937 cell line that
lacks functional BRCA1 when compared with the
HeLa cell line (Fig. 6A) as well as two BRCA1
defective lymphoblastoid cell lines (GM13705 and
GM14090, P5 0.0294 and P5 0.004, respectively)
when compared with the BRCA1 wt GM00893 (
Supporting Information Fig. S2A). However, when
we analyzed the colocalization of APBs with telo-
meres, we did not observe any significant differ-
ence between 408 and E14 cells, HCC1937 and
HeLa cells, or GM13705/GM14090 and GM00893
(Fig. 6B and Supporting Information Figs. S2A–
2C).
It has been shown recently that BLM colocal-
izes with BRCA1 within telomeres in ALT-
positive human cells (Acharya et al., 2014). The
BLM RecQ helicase functions at telomeres to reg-
ulate the D-loop formation following strand inva-
sion and may also be involved in resolving
recombination events in mortal and telomerase-
positive cells as well as in ALT-positive human
cells (Cheng et al., 2006; Acharya et al., 2014). We
did not find any difference in the levels of BLM-
positive foci between the E14 and 408 cells (Fig.
6C), whereas the levels of BRCA1 foci including
its colocalization with telomeres were found to be
significantly lower in the BRCA1 defective human
and mouse cells as expected ( Supporting Informa-
tion Figs. S3C and 3D). By contrast, we observed
a significant difference in the frequencies of
BLM-positive foci between the HCC1937 cell
line and the HeLa and U2OS cell lines (Fig. 6C).
However, when we analyzed colocalization of
BLM with telomeres we found that the 408 and
HCC1937 cell lines had significantly fewer coloc-
alizations with telomeres than the BRCA1 wt cells
lines (E14 and U2OS) (Fig. 6D and Supporting
Information Fig. S2D). This could be due to the
fact that BRCA1 is required for BLM colocaliza-
tion at telomeres (Fig. 6F and Supporting Infor-
mation Figs. S2E and S4B) as suggested
previously (Acharya et al., 2014).
A recent study indicated that mutations in
ATRX (alpha thalassemia/mental retardation syn-
drome X-linked) are associated with ALT activa-
tion in 90% of human ALT-positive cells (Lovejoy
et al., 2012). As expected, the U2OS cell line did
not show staining with the ATRX antibody in con-
trast to nonALT cell lines ( Supporting Informa-
tion Fig. S3A). No differences were observed in
the frequencies of ATRX-positive foci between
the 408 and E14 cell lines, or the HeLa and
HCC1937 cell lines (Supporting Information Fig.
S3A). Furthermore, no differences were observed
in colocalization between ATRX-positive foci and
telomeres between the 408 and E14 cell lines or
the HeLa and HCC1937 cell lines ( Supporting
Information Figs. 3A and 3B). When we looked
for colocalization of ATRX with telomeres, we did
not find any significant differences between in
ATRX colocalization with telomeres in the mESC
E14 and 408 cell lines ( Supporting Information
Figs. S3A and 3B), whereas the two mESC lines
showed high frequencies of ATRX in contrast to
published work where ATRX was mutated in the
ALT-positive human cells, including U2OS
(Lovejoy et al., 2012). Finally, when we looked at
colocalization of BRCA1 with ATRX and BLM
(Figs. 6E and 6F, Supporting Information Figs.
S2E and S4), a high ATRX colocalization in the
telomerase-positive cells (HCC1937 and HeLa),
was observed, which is in-line with previous obser-
vation, highlighting the fact that ALT marker
activity seen in the human BRCA1 defective sam-
ple, such as T-SCE, APBs, shorter and heteroge-
neous telomeres, may be due to ALT activity in
these cells but may not directly be involved in
maintaining telomere length as this is carried out
by the telomerase enzyme ( Supporting Informa-
tion Fig. S3E). However, further experiments are
needed to prove this hypothesis.
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Figure 6. Double immunofluorescence analysis of APBs, BRCA1,
ATRX, BLM in the human and mouse cells: (A and B) Total number of
ALT-associated PML bodies (APBs) in the human and mouse cells.
There were significantly higher levels of APBs in the U2OS ALT-
positive human cells and the Brca1 defective mESC 408; however, the
levels of APBs associated with telomeres were not significantly differ-
ent in the mESC 408 but was much higher in the U2OS cells. (C and
D) Reduced BLM foci were observed in the U2OS ALT-positive human
cells but not in the ALT negative human or the ALT-positive mouse
cells. However, BLM colocalizations with telomeres were significantly
higher in the U2OS and Brca1 wt mESC E14. (E) Colocalization of
BRCA1 with ATRX, and (F) BRCA1 with BLM, reveal differences
between human and mouse cells. A minimum of 50 cell nuclei was ana-
lyzed in two-independent experiments in all the samples shown above.
The error bars represent min/max in the whisker box plot and the
gray dotted line indicates mean in the scatter graphs. t-Test used for
statistical analysis with alpha set at 0.05.
DISCUSSION
Previous studies have shown that defects in
BRCA1 cause telomere alterations including
increased frequencies of telomeric fusion and telo-
mere shortening (Al-Wahiby and Slijepcevic, 2005;
Cabuy et al., 2005, 2008; French et al., 2006;
McPherson et al., 2006) thus suggesting an active
role of BRCA1 in telomere maintenance. Here, we
provide further evidence for the BRCA1 involve-
ment in telomere damage maintenance generated
spontaneously or after exposure to ionizing radia-
tion (Figs. 2D–2F, 4B and 4D, and Supporting
Information Fig. S5). Furthermore, there is evi-
dence that BRCA1 colocalizes with APBs in ALT-
positive cells (Acharya et al., 2014). The results
presented in this paper also support earlier find-
ings and provide further evidence for the role of
BRCA1 in telomere homeostasis. Similarly to cells
lacking BLM and WRN, proteins affected in
Bloom and Werner syndrome patients (Salk et al.,
1985; Laud et al., 2005), we have shown that
BRCA1 defective cells harbor high frequencies of
T-SCEs (Figs. 1A and 3A). However, we did not
observe any increases in the T-SCEs levels in the
HCC1937 cell line (data not shown) similar to pre-
viously published data (Al-Wahiby and Slijep-
cevic, 2005). In contrast, the levels of T-SCEs in
the ALT-positive U2OS cells were much higher
than in the ALT-negative HeLa cells as shown
previously (Anjomani Virmouni et al., 2015). Inter-
estingly, the frequencies of T-SCEs are also ele-
vated in BRCA2 defective cells (Sapir et al., 2011;
Bodvarsdottir et al., 2012). Given that T-SCEs are
one of the hallmarks of ALT this prompted us to
employ the CC assay, a method that detects ALT
unequivocally. Our results suggest that mouse
cells lacking functional Brca1 show a greater pro-
pensity for ALT than their Brca1 proficient coun-
terparts (Fig. 5A). This trend was also evident in
the case of human BRCA1 defective cells albeit but
the difference was not statistically significant (Fig.
5B) possibly suggesting a tighter suppression of
ALT activity in human cells than in mouse cells.
Previous reports have shown that ALT and telo-
merase can coexist in the same cells. This is par-
ticularly evident in the case of mouse cells. For
example, when an external DNA sequence was
attached to a single mouse telomere this sequence
was copied by other telomeres in somatic cells but
not in the germ-line cells (Neumann et al., 2013).
This suggests that ALT is heavily suppressed in
the mouse germ-line for unknown reasons. Even
though human and mouse cells differ significantly
in terms of telomere length maintenance, and
ALT may be more tightly regulated in human
somatic cells (Fig. 5B), telomerase and ALT coex-
ist also in human cells (Henson et al., 2002).
Taken together these results point to a scenario in
which telomere homeostasis is not a simple game
of a single mechanism (telomerase or ALT) but
rather a complex interplay of at least two mecha-
nisms (telomerase and ALT), which may operate
differently in different species or in different tis-
sues from the same species (Henson et al., 2002).
Interestingly, cells from Friedreich ataxia
(FRDA) patients show some evidence for elevated
ALT markers. For example, the frequencies of
APB-positive foci and T-SCEs are elevated in
comparison to control cells (Anjomani Virmouni
et al., 2015). Even though this study did not
employ the CC assay to assess the ALT activity
more conclusively it is extremely rare that primary
human cells show elevated APB staining and T-
SCE frequencies. FRDA is a neurological disorder
characterized by the expansion of GAA repeats
within the FXN gene (Campuzano et al., 1996).
The expansion have been linked with potential
defects in mismatch repair (MMR) (Ezzatizadeh
et al., 2012). There is some evidence that ALT is
activated in gastric cancer cells featuring an MMR
defect (Omori et al., 2009) and in the HCT15
colon cancer cell line defective in the MMR pro-
tein hMSH6 when telomerase is inhibited
(Bechter et al., 2004). Therefore, it is possible that
MMR defects alter the balance of telomere home-
ostasis in favor of ALT.
By the same token, our results argue that defec-
tive BRCA1 alters telomere homeostasis in favor of
ALT, perhaps acting as its de-repressor. This find-
ing may have implications for cancer therapy
based on targeting telomere maintenance.
Attempts to suppress telomerase as part of cancer
therapy are likely to lead to a positive selection for
cells in which ALT is de-repressed. Thus, the
telomerase-based therapy may not work on its
own without ensuring that the ALT pathway
remains repressed. Further research is needed to
identify potential ALT activators and repressors.
Our results are consistent with the view that nor-
mal BRCA1 acts as a repressor of ALT.
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